JUN 1 0 2005

CE

TRADE TRADE STATE TO TRADE STATE TO TRADE TRADE

CERTIFICATE OF MAILING

with the United States Postal Service as Express Mail, Express Mail Label Number EV590690150US with sufficient postage, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450, on

June 10, 2005		
Date of Deposit		
Vita G. Conforti Reg. No. 39,639		
Name of Applicant, Assignee or		
Registered Representative		
Vitachet		
Signature		
lacksquare		
June 10, 2005		
Date of Signature		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Francisco et al.		
Serial No.: 09/724,406		Group Art Unit: 1642
Filed: November 28, 2000		Examiner: Yu, Misook
For:	RECOMBINANT ANTI- CD30 ANTIBODIES AND USES THEREOF	

STATEMENT OF ATTORNEYS FOR APPLICANTS REGARDING PERMANENCE AND AVAILABILITY OF DEPOSITED MICROORGANISMS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I, an attorney for the Applicants in the above captioned application, declare and state that:

- 1. I represent Seattle Genetics, Inc., the later having a place of business at 21823 30th Drive SE, Bothell, Washington, 98021, and being the present assignee of the application.
- I am Director of Intellectual Property for Seattle Genetics, Inc. since July 2003.
- 3. That hybridoma AC10 secreting monoclonal antibody AC10 was deposited with the American Type Culture Collection (ATCC), at 10801 University Boulevard, Manassas, Va. 20110-2209, USA., on April 26, 2005, in compliance with the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure on behalf of the Applicants and Seattle Genetics, Inc. The deposited hybridoma was assigned ATCC accession number PTA-6679.
- 4. I hereby assure the United States Patent and Trademark Office and the public that (a) all restrictions on the availability to the public of the hybridoma referred to in paragraph 3 above will be irrevocably removed upon issuance of a Untied States patent making reference to the hybridoma; (b) the hybridoma will be maintained for a period of at least five years after the most recent request for the furnishing of a sample of the deposited hybridoma was received by the ATCC and, in any case, for a period of at least 30 years after the date of deposit; (c) should the deposit become non-viable it will be replaced by the Applicants; and (d) access to the hybridoma will be available to the Commissioner during the pendency of the patent application or to one determined by the Commissioner to be entitled to the hybridoma under 37 CFR 1.14 and 35 USC 122.
- 5. I declare further that all statements made in this Declaration of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section

1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

Dated: June 10, 2005

Vita G. Conforti

Registration No. 39,639 Attorney for Applicants

SEATTLE GENETICS, INC. 21823 30th Drive SE Bothell, Washington 98021 Telephone: (425) 527-4122

Fax: (425) 527-4123